What is Vyriad?
Vyriad is a pioneering clinical-stage biotechnology firm dedicated to the development of novel virus-based therapeutics, with an initial emphasis on proprietary oncolytic virus therapies designed to treat cancers that currently have significant unmet medical needs. Established by leading scientists from Mayo Clinic and the University of Miami, Vyriad leverages platforms derived from vesicular stomatitis virus (VSV), measles, and picornaviruses. These viruses are engineered to selectively target and destroy cancer cells, thereby stimulating potent antitumor immune responses that can lead to complete tumor eradication and prevent disease recurrence. The company's lead platform, based on VSV, is currently undergoing evaluation in ongoing Phase 1-2 clinical trials across a spectrum of cancer types. Vyriad has also established a significant strategic alliance with Regeneron Pharmaceuticals, Inc., focusing on the discovery and development of new oncolytic virus treatments by combining Vyriad's VSV platform with Regeneron's expertise in PD-1 inhibitors and antibody discovery.
How much funding has Vyriad raised?
Vyriad has raised a total of $95M across 2 funding rounds:
Series A
$10M
Series B
$85M
Series A (2017): $10M, investors not publicly disclosed
Series B (2025): $85M led by Mr. Harry Stine, Mirae Asset, Mayo Clinic, and Regeneron
Key Investors in Vyriad
Mayo Clinic
Mayo Clinic is a globally recognized nonprofit healthcare organization renowned for its integrated clinical practice, education, and medical research, contributing significantly to medical advancement and healthcare innovation.
Regeneron
Regeneron is a leading biotechnology company focused on discovering, developing, and commercializing innovative medicines for serious diseases, utilizing advanced science and proprietary technologies to create life-changing treatments.
Mr. Harry Stine
Mr. Harry Stine is an investor participating in the funding round, contributing capital to support Vyriad's development of virus-based therapeutics.
What's next for Vyriad?
With the recent major strategic investment, Vyriad is well-positioned to accelerate the clinical development and potential commercialization of its oncolytic virus therapies. The substantial enterprise-level funding indicates strong investor confidence in the company's technology and its potential to address critical gaps in cancer treatment. This capital will likely fuel further clinical trials, expand research and development efforts, and potentially scale up manufacturing capabilities. The ongoing collaboration with Regeneron is also a key strategic asset, promising synergistic advancements in the field of immuno-oncology and reinforcing Vyriad's trajectory toward becoming a leader in virus-based cancer therapeutics.
See full Vyriad company page
